WATCH: Section 112 – Where has the dust settled?

David Gindler of Orrick discusses the US Supreme Court’s ruling in Amgen v. Sanofi and what it means for ongoing Section 112 litigation. The session considers how the decision has been applied – and how it may continue to be applied – by the Federal Circuit, district courts, and the PTAB, with a focus on its relevance to the life sciences sector.